BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 26142924)

  • 1. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
    Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
    Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Real-life experience': recurrence rate at 3 years with Hexvix
    Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
    World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).
    Miyake M; Nishimura N; Inoue T; Suzuki S; Fujii T; Owari T; Hori S; Nakai Y; Toritsuka M; Nakagawa H; Tsukamoto S; Anai S; Torimoto K; Yoneda T; Tanaka N; Fujimoto K
    Trials; 2021 Feb; 22(1):136. PubMed ID: 33579327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
    Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
    Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial Experience of Photodynamic Diagnosis-Assisted Transurethral Resection of Bladder Tumor (PDD-TURBT)].
    Sugino Y; Nishikawa K; Kato M; Sasaki T; Kato M; Masui S; Yoshio Y; Kanda H; Sugimura Y; Inoue T
    Hinyokika Kiyo; 2021 Jul; 67(7):303-308. PubMed ID: 34353010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Nishimura N; Miyake M; Nakahama T; Miyamoto T; Nishimoto K; Oyama M; Matsushita Y; Miyake H; Fukuhara H; Inoue K; Kobayashi K; Matsumoto H; Matsuyama H; Fujii T; Hirao Y; Fujimoto K
    Int J Urol; 2023 Dec; 30(12):1112-1119. PubMed ID: 37605814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.
    Fukuhara H; Yamamoto S; Lai HW; Karashima T; Kurabayashi A; Furihata M; Inoue K
    Photodiagnosis Photodyn Ther; 2022 Jun; 38():102757. PubMed ID: 35151889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
    Kobayashi K; Matsuyama H; Oka S; Nakamura K; Misumi T; Hiroyoshi T; Ito H; Isoyama N; Hirata H; Matsumoto H; Shiraishi K
    Photodiagnosis Photodyn Ther; 2023 Mar; 41():103294. PubMed ID: 36681259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
    Matsushita Y; Miyake M; Nishimura N; Nishimoto K; Fukuhara H; Kobayashi K; Oyama M; Inoue K; Matsuyama H; Fujimoto K; Miyake H
    Int J Clin Oncol; 2024 Feb; 29(2):205-212. PubMed ID: 38112832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-Risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?
    Tadrist A; Gondran-Tellier B; McManus R; Al Balushi K; Akiki A; Gaillet S; Delaporte V; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
    J Endourol; 2021 Jul; 35(7):1042-1046. PubMed ID: 33626963
    [No Abstract]   [Full Text] [Related]  

  • 17. Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results.
    de la Rosette J; Martov A; Hurle R; Favre G; Mamoulakis C; Castanheira de Oliveira M; Stenzl A; Linares-Espinós E; Trelles Guzmán CR; Gravas S; Knoll T; Boz MY; Herrmann T; Laguna P
    World J Urol; 2022 Mar; 40(3):727-738. PubMed ID: 34741631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.
    Yu G; Rice S; Heer R; Lewis R; Vadiveloo T; Mariappan P; Penegar S; Clark E; Tandogdu Z; Hall E; Vale L
    Eur Urol Open Sci; 2023 Jul; 53():67-77. PubMed ID: 37441343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the short-term outcomes and complications of monopolar and bipolar transurethral resection of non-muscle invasive bladder cancers: a prospective, randomized, controlled study.
    Bolat D; Gunlusoy B; Degirmenci T; Ceylan Y; Polat S; Aydin E; Aydogdu O; Kozacioglu Z
    Arch Esp Urol; 2016 Jun; 69(5):225-33. PubMed ID: 27291558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.
    Mariappan P; Zachou A; Grigor KM;
    Eur Urol; 2010 May; 57(5):843-9. PubMed ID: 19524354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.